Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Trend | Peers | Company |
|---|---|---|
| Is return on equity increasing? | Yes | Yes |
| Is net profit margin increasing? | Yes | Yes |
| Is asset turnover increasing? | Yes | No |
| Is equity multiplier increasing? | No | Yes |
| Competitors Used |
|---|
| Supernus Pharmaceuticals, Inc. |
| Prestige Consumer Healthcare Inc. |
| Amneal Pharmaceuticals, Inc. |
| Assertio Holdings, Inc. |
| Corcept Therapeutics Incorporated |
| Return on Equity Benchmarks | ||||||||
| Comparable Companies | ||||||||
| SUPN | PBH | AMRX | ASRT | CORT | 29A | |||
| Return On Equity | ||||||||
| Latest Twelve Months | 6% | 12% | 13% | -25% | 22% | 20% | ||
| Fiscal Year - 1 | 0% | 13% | -53% | -183% | 21% | 24% | ||
| Fiscal Year - 2 | 7% | -5% | -39% | 67% | 23% | 19% | ||
| Fiscal Year - 3 | 7% | 14% | 3% | -2% | 25% | 15% | ||
| Fiscal Year - 4 | 19% | 13% | 34% | -50% | 24% | 0% | ||
| Fiscal Year - 5 | 22% | 13% | -98% | -156% | 29% | 14% | ||
| Average | 10% | 10% | -23% | -58% | 24% | 15% | ||
| Median | 7% | 13% | -18% | -37% | 23% | 17% | ||
| Benchmarks | Ticker | |||||||
| Supernus Pharmaceuticals, Inc. | NasdaqGM:SUPN | |||||||
| Prestige Consumer Healthcare Inc. | NYSE:PBH | |||||||
| Amneal Pharmaceuticals, Inc. | NasdaqGS:AMRX | |||||||
| Assertio Holdings, Inc. | NasdaqCM:ASRT | |||||||
| Corcept Therapeutics Incorporated | NasdaqCM:CORT | |||||||
| Financial Performance | ||||||||
| Comparable Companies | ||||||||
| (in millions) | SUPN | PBH | AMRX | ASRT | CORT | 29A | ||
| Latest Fiscal Year | Dec-24 | Mar-25 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
| LTM Period | Mar-25 | Mar-25 | Mar-25 | Mar-25 | Mar-25 | Mar-25 | ||
| Revenues | ||||||||
| Latest Twelve Months | 668 | 1,138 | 2,830 | 119 | 685 | 731 | ||
| Fiscal Year | 662 | 1,138 | 2,794 | 125 | 675 | 732 | ||
| Fiscal Year - 1 | 608 | 1,125 | 2,394 | 152 | 482 | 644 | ||
| Fiscal Year - 2 | 667 | 1,128 | 2,212 | 156 | 402 | 499 | ||
| Fiscal Year - 3 | 580 | 1,087 | 2,094 | 111 | 366 | 438 | ||
| Fiscal Year - 4 | 520 | 943 | 1,993 | 108 | 354 | 350 | ||
| Fiscal Year - 5 | 393 | 963 | 1,626 | 230 | 306 | 322 | ||
| Net Income | ||||||||
| Latest Twelve Months | 62 | 215 | (13) | (31) | 133 | 142 | ||
| Fiscal Year | 74 | 215 | (117) | (22) | 140 | 160 | ||
| Fiscal Year - 1 | 1 | 209 | (84) | (332) | 105 | 138 | ||
| Fiscal Year - 2 | 61 | (82) | (130) | 110 | 101 | 91 | ||
| Fiscal Year - 3 | 53 | 205 | 11 | (1) | 113 | 62 | ||
| Fiscal Year - 4 | 127 | 165 | 91 | (28) | 106 | 1 | ||
| Fiscal Year - 5 | 113 | 142 | (362) | (217) | 94 | 49 | ||
| Total Assets | ||||||||
| Latest Fiscal Quarter Prior | 1,304 | 3,318 | 3,456 | 282 | 656 | 1,574 | ||
| Latest Fiscal Quarter | 1,347 | 3,402 | 3,365 | 286 | 846 | 1,626 | ||
| Fiscal Year | 1,368 | 3,402 | 3,501 | 285 | 841 | 1,577 | ||
| Fiscal Year - 1 | 1,278 | 3,318 | 3,473 | 286 | 622 | 1,513 | ||
| Fiscal Year - 2 | 1,703 | 3,354 | 3,799 | 414 | 583 | 742 | ||
| Fiscal Year - 3 | 1,689 | 3,671 | 3,940 | 327 | 424 | 672 | ||
| Fiscal Year - 4 | 1,504 | 3,429 | 4,006 | 303 | 572 | 631 | ||
| Fiscal Year - 5 | 1,160 | 3,514 | 3,666 | 527 | 412 | 587 | ||
| Fiscal Year - 6 | 978 | 3,441 | 4,353 | 933 | 312 | 514 | ||
| Common Equity | ||||||||
| Latest Fiscal Quarter Prior | 929 | 1,655 | (64) | 134 | 548 | 672 | ||
| Latest Fiscal Quarter | 1,031 | 1,835 | (132) | 109 | 683 | 751 | ||
| Fiscal Year | 1,036 | 1,835 | (109) | 121 | 680 | 732 | ||
| Fiscal Year - 1 | 922 | 1,655 | 20 | 138 | 507 | 639 | ||
| Fiscal Year - 2 | 886 | 1,447 | 298 | 226 | 502 | 529 | ||
| Fiscal Year - 3 | 816 | 1,578 | 360 | 102 | 376 | 446 | ||
| Fiscal Year - 4 | 745 | 1,358 | 303 | 56 | 523 | 402 | ||
| Fiscal Year - 5 | 595 | 1,171 | 232 | 58 | 371 | 381 | ||
| Fiscal Year - 6 | 453 | 1,096 | 505 | 220 | 276 | 332 | ||